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Abstract
Background: Milan and University of California San Francisco (UCSF) Criteria have been used for
selection of patients with hepatocellular carcinoma (HCC) for liver transplantation (LTx). The aims of this
study were to analyse the results of LTx for HCC in Australia and New Zealand with emphasis on the
effects of discordance between pre-LTx radiological and post-LTx pathological staging.
Methods: A total of 186 LTx for HCC carried out between July 1985 and August 2003 were included.
Patients were categorized according to the Milan and UCSF Criteria.
Results: The median follow-up was 6.55 years (range 2.96–20.93 years). Pre-LTx factors associated with
better survival include tumour size5 cm, number of tumours3, staging within Milan and UCSF Criteria
and more recent transplantation (1996–2003). In all, 14 patients had a pre-LTx stage outside the Milan but
within the UCSF Criteria. One- and 5-year patient survival rates were, respectively, 88% and 74% within
the Milan Criteria, and 87% and 73% within the UCSF Criteria. Vascular invasion, capsular invasion,
lymph node invasion and pathological stage outside UCSF Criteria were associated with poor outcome.
Of patients within the Milan and UCSF Criteria pre-LTx, 24% and 18%, respectively, were outside the
same criteria post-LTx. These patients had poorer survival rates.
Conclusions: The use of the UCSF Criteria in this cohort increased the number of patients eligible for
LTx without compromising 5-year survival rates. Patients whose explant tumours were outside the Milan
or UCSF Criteria had poorer outcomes compared with those whose explants remained within these
criteria.
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Introduction
Liver transplantation (LTx) is the treatment of choice for patients
with hepatocellular carcinoma (HCC) on a background of liver
cirrhosis. In most centres, only patients whose HCC meets the
Milan Criteria are considered for LTx.1 These criteria, based on
tumour size and number, are surrogate markers for favourable
tumour biology. However, LTx patients outside these criteria can
still expect a modest 5-year survival (25–45%),2 indicating that
size and number are not reliable determinants of tumour biology.
Nevertheless, in the absence of more specific criteria to assess
tumour biology preoperatively, tumour size and number remain
the most important selection criteria for HCC patients undergo-
ing LTx. They are, in fact, surrogate markers for vascular invasion,
which indicates a poor prognosis.3
Inevitably there is a delay between placing the patient on the
waiting list and subsequent LTx, during which tumour progres-
sion may occur. Periodic radiological imaging is performed to
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keep track of tumour status4 and those who progress beyond
specific criteria, such as the Milan or University of California San
Francisco (UCSF) Criteria,5 are removed from waiting lists
because of their predicted poorer post-transplant outcome.
The aims of this study were two-fold. Firstly, we aimed to deter-
mine the outcome of all patients who underwent LTx for HCC in
Australia and New Zealand over an 18-year period and to identify
the impact of pre- and post-LTx factors, including the application
of the Milan and UCSF Criteria. Secondly, we wanted to examine
the effect of discordance between pre-LTx radiological staging
(using the Milan and UCSF Criteria) and post-LTx pathological
staging on LTx outcome.
Materials and methods
A retrospective analysis was performed of all patients who under-
went LTx for HCC in Australia and New Zealand between 1985
and 2003. All LTx patients for whom HCC was confirmed in the
pathology of the explanted liver were included. All transplants
were performed using deceased organs. Data examined included
details of patient demographics, disease aetiology, preoperative
imaging results and pre-transplant tumour treatment, as well as
postoperative outcomes, including histopathological findings,
patient survival, tumour recurrence and further treatments.
Pre-transplant variables analysed included age, sex, serum
a-fetoprotein (a-FP) levels and radiological tumour size and
number. Any pre-LTx treatment of the tumour by any modality
was also noted. These factors were analysed with respect to patient
survival and recurrence-free survival. The Milan and UCSF Cri-
teria as previously published1,5 were applied to this cohort of
patients using both pre-LTx (radiological) and post-LTx (patho-
logical) classification.
The effect of era of LTx on patient survival was evaluated. We
divided the cohort into three eras. The early era (1985–1990),
when LTx was first established in Australia, was marked by a lack
of objective selection criteria for transplanting patients with
known HCC and by suboptimal radiological imaging. During the
middle era (1990–1995) selection criteria were more restrictive,
whereas the latter era (1996–2003) followed the introduction of
the Milan Criteria.
The pathological features of the explanted liver including
tumour size and number, differentiation of tumour, presence of
vascular or capsular invasion and involvement of lymph nodes
were analysed. The effects of additional treatment post-LTx on
survival were also evaluated. In addition, we sought to identify the
prognostic indicators for survival after LTx in this cohort of
patients.
Finally, we examined the effect of discordance between radio-
logical stage and pathological stage in patients who satisfied the
Milan or UCSF Criteria at listing. Any discordance in either
number of tumours and/or tumour size resulting in staging
outside the two respective criteria sets was considered a ‘stage
migration’ for analysis purposes. Survival outcomes in this stage
migration group were compared with outcomes for patients
whose explanted tumours remained within preoperative Milan
and UCSF Criteria, respectively.
Data analysis
Univariate analysis was carried out using the log rank test with
patient and graft survival difference as the outcome measures.
Continuous variables such as age and tumour size were converted
into categorical variables according to previously published
ranges.1,5 Determinants that were significant on univariate analy-
sis were then subjected to multivariate analysis with Cox multi-
regression analysis. All statistical analyses were carried out using
spss Version 11.0.1 (SPSS, Inc., Chicago, IL, USA).
Results
In the period between July 1985 and Aug 2003, a total of 186
patients with HCC underwent LTx within the six liver transplant
units in Australia and New Zealand. The presence of tumour was
confirmed from the histology of the explanted tumour. The
majority of the patients were males (83%). Their mean age was
52.8 years (range 12–73 years). Overall patient survival rates fol-
lowing LTx were 83.7% at 1 year, 75.8% at 3 years and 67.1% at 5
years (Fig. 1).
Aetiologies of the primary liver disease and cirrhosis are shown
in Table 1. Viral hepatitis was the major cause of the primary liver
disease in 70% of cases.
A total of 146 (78.5%) patients were known to have HCC
preoperatively based on a combination of radiological imaging
(computed tomography [CT] scans), biopsy or serum a-FP assay.
In 38 patients, the tumour was diagnosed incidentally from the
histology of the explanted liver. Pre-transplant CT scans allowed
us to stage tumours in 143 patients using the Milan and UCSF
Patient survival, months
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Figure 1 Overall patient survival following liver transplantation in
hepatocellular carcinoma (1985–2003)
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Criteria for 112 (71.1%) and 126 (88.1%) patients, respectively.
Those staged within the Milan or UCSF Criteria had better sur-
vival than patients outside the criteria (Fig. 2a, b) (P < 0.02).
Pre-transplant variables
The effects of various pre-transplant variables on patient survival
are shown in Table 2. Both HCC staged within either the Milan or
UCSF Criteria (P < 0.02) and LTx performed in the latest era
(1996–2003) were associated with significantly better patient
survival. A number of tumours 3 was associated with better
outcome. Age and sex did not influence outcome. In 56 patients,
HCC was treated pre-LTx. The majority (n = 29) of these patients
underwent chemoembolization. The various modalities of pre-
LTx treatment performed are shown in Table 3. Patients who had
or required pre-transplant treatment had similar outcomes.
In the evaluation of patient survival with respect to LTx era, the
16 patients who underwent LTx during 1985–1990 had the poorest
outcome (Fig. 3). During the middle era (1991–1995), only 13
patients were transplanted as a result of more cautious patient
selection, but the best outcomes were achieved. The most recent
era, after the introduction of the Milan Criteria, saw the largest
number of HCC patients transplanted (n = 157) and witnessed
survival outcomes comparable with those of the middle era.
Using Cox regression multivariate analysis, the significant
factors associated with poorer patient survival outcome on mul-
tivariate analysis included a tumour number >3 and tumour size
>5 cm. Being within the Milan or UCSF Criteria on pre-LTx radi-
ology were independent predictors of a good outcome on multi-
variate analysis.
Tumour characteristics
Explanted tumour sizes >5 cm or >6.5 cm were associated with
poorer patient survival following LTx. Vascular micro- or macro-
scopic invasion, capsular invasion and the presence of positive
lymph nodes were associated with significantly poorer post-LTx
outcomes. Surprisingly, the degree of tumour differentiation did
not have a significant effect on outcome. Tumours that were
outside UCSF pathological criteria were associated with poorer
longterm outcomes (Fig. 4). Table 4 shows tumour characteristics.
Using Cox regression multivariate analysis, vascular invasion
(macro- and microscopic), tumour number (>3), tumour size
(>5 cm, >6.5 cm), and tumours exceeding the Milan and UCSF
Criteria on explant pathology were independent predictors of
poorer survival.
Recurrence-free survival
Factors that significantly influenced HCC recurrence-free survival
post-transplantation were identical to those affecting patient sur-
vival, as shown in Table 5.
On follow-up, 157 (84%) patients remained tumour-free.
Recurrence of tumour occurred in 29 (16%) patients, two of
whom survived beyond 5 years but not beyond 7 years.
Discordance between radiological and pathological
stage and effect on outcome
Complete imaging information for accurate preoperative tumour
staging according to the Milan and UCSF Criteria, as well as
explant tumour pathology, was available for 137 patients.
Table 1 Aetiology of liver disease
n %
HBV 61 33.0
HCV 52 28.0
HBV + HCV 16 9.0
Alcohol 16 9.0
Cryptogenic 11 6.0
Haemochromatosis 6 3.2
Primary biliary cirrhosis 5 2.7
Primary sclerosing cholangitis 2 1.1
Unknown 1 0.6
HBV, hepatitis B virus; HCV, hepatitis C virus
Patient survival, months
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Figure 2 Survival curves for patients staged using the (a) Milan and
(b) University of California San Francisco Criteria. There is a signifi-
cant decrease in patient survival in patients staged outside the Milan
Criteria on pre-liver transplant imaging (log rank P < 0.02)
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Of the 108 patients in whom HCC fell within the Milan Criteria
on pre-LTx staging, 26 (24%) were outwith the Milan Criteria on
explant pathology. Of these 26 patients, 10 had more than three
tumours, five had tumours >5 cm and tumours in 11 patients
exceeded both size and number criteria. This group of patients had
poorer survival than even those who were outwith the Milan
Criteria prior to LTx (Fig. 5). Tumour characteristics fell within the
UCSF Criteria on pre-LTx staging for 125 patients, 22 (18%) of
whom migrated outside UCSF Criteria on explant pathology. This
group had poorer survival compared with those whose explanted
liver characteristics remained within the UCSF Criteria (Fig. 6).
Discussion
Recently, commentators have suggested that despite the usefulness
of both the Milan and UCSF Criteria for selecting patients with
HCC for LTx, staging criteria perhaps need to move beyond
tumour size and number.6,7 These parameters are surrogate
Table 2 Overall survival of hepatocellular carcinoma patients after liver transplantation based on preoperative variables
Parameters n Survival, % P-value
1 year 3 years 5 years
Gender
Male 155 82.6 74.2 61.9 0.3072
Female 31 90.0 83.3 64.0
Age, years
40 19 83.3 83.3 59.8 0.6749
41–50 56 91.1 78.6 76.8
51–60 79 73.8 68.8 66.1
>60 32 96.9 84.4 59.5
a-fetoprotein, KIU/l
<50 119 86.6 81.5 71.2 0.2072
50–200 33 84.9 72.7 65.2
>200 30 73.3 56.7 53.1
Number of tumours
>3 11 72.7 72.7 32.7 0.0412
3 142 83.8 73.9 67.6
Tumour size
>5 cm 11 54.6 36.4 18.2 0.0002
5 cm 131 87.0 79.4 72.4
Milan Criteria
Within 112 88.4 79.5 74.3 0.0164
Outside 31 71.0 64.5 43.0
UCSF Criteria (radiological)
Within 126 87.3 78.6 73.1 0.0009
Outside 17 64.7 58.8 27.5
Pre-transplant treatment of HCC
Yes 56 83.2 65.2 60.9 0.9736
No 121 87.5 78.6 67.9
Unknown 9 – – –
Era of transplant
1985–1990 16 62.5 50.0 37.4 0.0500
1991–1995 13 92.3 92.3 76.9
1996–2003 157 85.4 77.1 69.3
Diagnosis of HCC
Pre-LTx 146 82.2 72.6 64.9 0.1336
Incidental 38 89.5 86.8 74.3
UCSF, University of California San Francisco; HCC, hepatocellular carcinoma; LTx, liver transplantation
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markers of tumour biology, particularly of vascular invasion.3 We
now know that some patients whose tumour characteristics fall
within these criteria do poorly after LTx and others, whose HCC
exceed the criteria, do well.2 In the absence of more specific readily
obtainable markers to assist us in differentiating good from
aggressive tumour biology, the Milan and UCSF Criteria (applied
pre-transplant) remain the current standards.
This series is unique in that all liver transplant units in Australia
and New Zealand participated in the study. The series spans a
period of almost two decades. During this period, overall 1- and
5-year patient survival rates following LTx for all indications
improved from 70% and 59% (1985–1989) to 91% and 83%
(2000–2004), respectively.8 This result is in line with similar
improvements demonstrated in other registries. This cohort of
HCC patients had a median follow-up of >6 years. The number of
LTx procedures as well as the results very much reflect the prevail-
ing management of HCC in patients with cirrhosis during three
time periods. The post-Milan Criteria era (1996–2003) was asso-
ciated with the largest number of transplants for HCC. Overall
5-year patient survival rates were 67.1%, and 74.3% and 73.1%,
respectively, for cases falling within the Milan and UCSF Criteria
(Fig. 2a, b), which compare favourably with rates in other pub-
lished series (Table 6).
The independent pathological variables that significantly influ-
enced outcome include tumour size, tumour number and vascular
invasion. These findings are consistent with previously published
data.1 It is of interest that the degree of differentiation was not
significant in the current series.
One of the aims of this study was to validate the prognostic
significance of the Milan and UCSF Criteria in this cohort of
patients. The results of applying both sets of criteria, based on
pre-LTx imaging, to this cohort of patients produced almost iden-
tical patient survival rates, similar to the original publications
from Milan and UCSF, respectively.1,5
According to our data, expanding the Milan Criteria to the
UCSF Criteria would increase the number of patients eligible for
LTx by 9.8% and would decrease post-transplant patient survival
by only 1.2%. Thus, the application of UCSF Criteria in this
cohort confirms the findings of other series which have demon-
strated that expanding the Milan Criteria to the UCSF Criteria
would not significantly compromise post-transplant survival. A
recent French series found that patient survival was inferior for
patients falling outside the Milan but within the UCSF Criteria.8
This may reflect the inclusion of an earlier cohort of LTx cases
(1985–1990), in which outcomes were poorer overall.4 Previous
retrospective series5,9,10 have revealed that only about 5% of
Table 3 Treatment of hepatocellular carcinoma prior to liver
transplantation
n
None 117
Missing data 5
Treated 56
Chemoembolization 29
Chemotherapy 3
Alcohol injection 4
Tamoxifen 1
Embolization 9
Multimodality 6
Resection 3
Radiofrequency ablation 1
Patient survival, months
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Figure 3 Patient survival rates following liver transplantation (LTx) in
hepatocellular carcinoma (HCC). In the first period (1985–1999),
some large and multiple HCC were transplanted with poor results
(P < 0.05). As a result, the second period (1991–1995) saw relatively
few transplants for this indication. The publication of the Milan
Criteria resulted in the highest number of LTx for HCC in the last era
(1996–2003)
Patient survival, months
12010896847260483624120
Within
Outside
72.7%
59.1%
36.0%
86.4% 
79.6%
76.7%
C
um
ul
at
iv
e 
su
rv
iv
al
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Figure 4 The pathological staging of the tumour using University of
California San Francisco (UCSF) Criteria was evaluated for patient
survival. When the explanted liver met UCSF Criteria, patient survival
was significantly improved (P < 0.0005). A similar trend was noted for
recurrence-free survival
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listed and subsequently transplanted patients exceeded the Milan
but adhered to UCSF Criteria, compared with the 9.8% in our
series.
With respect to disconcordance between pre-LTx staging and
explant pathological staging, it was not surprising that 24% and
18% of patients who were within Milan and UCSF Criteria,
respectively, exceeded the criteria on explant pathology. These
groups had significantly worse outcomes. The discordance in each
case was caused by inaccurate radiological staging or true tumour
progression between imaging and transplantation. Factors affect-
ing the latter include waiting time and tumour biology. Other
studies comparing pre-LTx staging with explant pathology found
an accuracy of around 60%.11 These findings have implications for
the frequency of restaging of HCC patients on waiting lists. Given
the relative shortage of donor livers and the need to best utilize
this scarce resource, more vigilant and frequent restaging may
result in delisting some of these patients and hence improve the
utility of donor organs. Two previous studies looking at the pro-
gression of HCC beyond the Milan Criteria in the explanted
liver revealed a much higher proportion (43%) of radiologically
under-staged (by Milan Criteria) explant HCC.4,12 Both studies
demonstrated similar decreased survival outcomes. The authors
suggested that increasing CT imaging surveillance to intervals
shorter than 3 months might be beneficial.4
Two recent studies have demonstrated that down-staging of
HCC with various modalities such as transarterial chemoembo-
lization (TACE) and radiofrequency ablation (RFA) may select a
group of patients outside the usual criteria who can be considered
for LTx with acceptable results. Yao et al. demonstrated that, in a
group of patients with large tumour, down-staging with RFA and
TACE can produce results as good as those for patients who fall
within the UCSF Criteria.13 However, as yet no survival benefit has
been demonstrated with TACE. The more recent study by a
German group demonstrated that the response of tumour to
Table 4 Overall survival of hepatocellular carcinoma patients after liver transplantation based on tumour characteristics
Parameters n Survival, % P-value
1 year 3 years 5 years
Largest tumour diameter
<5.0 cm 152 87.0 81.2 74.4 <0.0001
5.0 cm 24 54.2 33.3 20.1
<6.5 cm 161 85.7 78.3 71.8 0.0001
6.5 cm 15 53.3 40.0 13.3
Tumour number
>3 32 80.7 74.2 45.1 0.0026
3 144 85.4 76.4 73.0
Milan Criteria (explant)
Within 117 87.2 80.3 77.1 0.0002
Outside 59 74.6 62.7 46.1
UCSF Criteria
Within 132 86.4 79.6 76.7 <0.0001
Outside 44 72.7 59.1 36.0
Capsular invasion
Absent 157 84.7 79.6 71.7 0.0039
Present 19 79.0 42.1 30.1
Vascular invasion
None 142 86.8 81.9 74.1 <0.0001
Micro 14 85.7 64.3 64.3
Macro 20 55.0 30.0 13.3
Lymph nodes involvement
No 170 84.3 76.7 68.3 0.0034
Yes 6 50.0 16.7 16.7
Degree of differentiation
Well 38 89.5 81.6 75.3 0.3854
Moderate 67 85.1 74.6 64.8
Poor 21 81.0 71.4 71.4
UCSF, University of California San Francisco
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Table 5 Recurrence-free survival of hepatocellular carcinoma patients after liver transplantation based on tumour characteristics
Parameters n Survival, % P-value
1 year 3 years 5 years
Gender
Male 155 81.9 72.9 65.9 0.7488
Female 31 83.3 70.0 58.7
Age, years
40 19 88.9 72.2 60.1 0.8313
41–50 56 85.7 75.0 72.7
51–60 79 76.3 70.0 63.7
>60 32 87.5 75.0 57.9
a-fetoprotein, KIU/l
<50 119 85.7 77.3 70.3 0.1141
50–200 33 81.8 72.7 68.5
>200 32 70.0 56.7 46.4
Milan Criteria
Within 112 84.8 77.7 71.5 0.0202
Outside 31 77.4 58.1 42.3
UCSF Criteria (pre-LTx)
Within 126 84.1 77.0 70.6 0.0041
Outside 17 76.5 47.1 27.5
Pre-transplant treatment of HCC
Yes 56 85.7 76.8 68.1 0.8648
No 121 80.2 71.1 64.5
Era of transplant
1985–1990 16 56.3 31.3 25.0 0.0014
1991–1995 13 92.3 76.9 76.9
1996–2003 157 84.1 75.8 67.9
Tumour number
>3 32 74.2 67.7 45.4 0.0038
3 144 84.7 75.0 70.8
Largest tumour diameter
<5.0 cm 154 86.4 79.2 71.6 <0.0001
5.0 cm 22 58.3 29.2 25.0
<6.5 cm 161 84.5 77.0 69.7 0.0019
6.5 cm 15 60.0 26.7 20.0
Milan Criteria (explant)
Within 117 87.2 79.5 74.3 0.001
Outside 59 72.9 59.3 48.4
UCSF Criteria (explant)
Within 132 86.4 79.6 75.0 <0.0001
Outside 44 70.5 52.3 36.3
Capsular invasion
Absent 157 85.4 76.4 69.7 0.0053
Present 19 57.9 42.1 30.1
Vascular invasion
None 144 85.4 78.5 70.3 <0.0001
Micro 14 85.7 64.3 64.3
Macro 20 55.0 30.0 25.0
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TACE is a good prognostic indicator for subsequent transplant
outcome.14 In patients with large HCC that respond to TACE, the
survival outcome was acceptable. However, in patients who pro-
gressed while under treatment with TACE, the outcome was poor
despite the smaller tumour size in some cases. It would appear
from these two studies that a positive response to down-staging
perhaps reflects good tumour biology.
Conclusions
This unique Australasian study validated the use of the Milan and
UCSF Criteria for selection of patients with HCC for LTx. Expand-
ing the Milan Criteria to meet the UCSF Criteria did not decrease
5-year survival significantly. Overall, 24% and 18% of patients who
satisfied the Milan and UCSF Criteria, respectively, on pre-LTx
Figure 5 Patients in whom hepatocellu-
lar carcinoma (HCC) fell within the Milan
Criteria pre- and post-liver transplanta-
tion (LTx) had significantly better survival
rates than patients with HCC outside the
Milan Criteria in explanted liver. This dis-
cordance between pre- and post-LTx
characteristics probably reflects tumour
progression. Patients with HCC outside
the Milan Criteria on pre-LTx imaging had
worse outcomesPatient survival, months
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Figure 6 When the original pathological
staging University of California San Fran-
cisco (UCSF) Criteria are applied to pre-
LTx imaging, the survival trend mirrors
that in Fig. 5. Patients in whom tumour
progressed beyond the pre-LTx UCSF
Criteria did more badly than those whose
explanted liver remained within the
criteriaPatient survival, months
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Table 5 Continued
Parameters n Survival, % P-value
1 year 3 years 5 years
Lymph nodes involvement
No 172 83.7 73.8 66.4 0.011
Yes 6 33.3 16.7 16.7
Degree of differentiation
Well 38 92.1 76.3 73.2 0.3591
Moderate 67 80.6 71.6 63.1
Poor 21 76.2 76.2 70.3
UCSF, University of California San Francisco; LTx, liver transplantation; HCC, hepatocellular carcinoma
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imaging exceeded these limits in explant pathology, suggesting
either tumour progression or an under-estimation of disease on
imaging. This group of patients had poorer survival outcomes.
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